Transport-exclusion pharmacology to localize lactate dehydrogenase activity within cells by Niu, Xiangfeng et al.




Transport-exclusion pharmacology to localize





Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
RAPID COMMUNICATION Open Access
Transport-exclusion pharmacology to
localize lactate dehydrogenase activity
within cells
Xiangfeng Niu1†, Ying-Jr Chen1†, Peter A. Crawford2,3 and Gary J. Patti1,4*
Abstract
Background: Recent in vitro and in vivo work has shown that lactate provides an important source of carbon for
metabolic reactions in cancer cell mitochondria. An interesting question is whether lactate is oxidized by lactate
dehydrogenase (LDH) in the cytosol and/or in mitochondria. Since metabolic processes in the cytosol and
mitochondria are affected by redox balance, the location of LDH may have important regulatory implications in
cancer metabolism.
Methods: Within most mammalian cells, metabolic processes are physically separated by membrane-bound
compartments. Our general understanding of this spatial organization and its role in cellular function, however,
suffers from the limited number of techniques to localize enzymatic activities within a cell. Here, we describe an
approach to assess metabolic compartmentalization by monitoring the activity of pharmacological inhibitors that
cannot be transported into specific cellular compartments.
Results: Oxamate, which chemically resembles pyruvate, is transported into mitochondria and inhibits LDH activity
in purified mitochondria. GSK-2837808A, in contrast, is a competitive inhibitor of NAD, which cannot cross the inner
mitochondrial membrane. GSK-2837808A did not inhibit the LDH activity of intact mitochondria, but GSK-2837808A
did inhibit LDH activity after the inner mitochondrial membrane was disrupted.
Conclusions: Our results are consistent with some mitochondrial LDH that is accessible to oxamate, but
inaccessible to GSK-2837808A until mitochondria are homogenized. This strategy of using inhibitors with selective
access to subcellular compartments, which we refer to as transport-exclusion pharmacology, is broadly applicable
to localize other metabolic reactions within cells.
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Background
Most mammalian cells contain organelles that are
bounded by lipid membranes. The chemical reactions
occurring in each of these compartments are seques-
tered from the rest of the cell, thereby providing an op-
portunity to specialize metabolism in support of specific
organelle functions. Some examples include generating
harmful metabolic byproducts in organelles where they
can be neutralized (such as hydrogen peroxide in
peroxisomes), adjusting chemical concentrations to drive
reactions in a direction that they may not proceed in
other parts of the cell (such as using a proton gradient
to fuel ATP synthesis in mitochondria), and harboring
anabolic and catabolic reactions in different compart-
ments to limit unproductive futile cycling (such as fatty
acid synthesis in the cytosol and fatty acid oxidation in
mitochondria) [1, 2].
Despite increasing evidence that metabolic
compartmentalization is essential to various cellular func-
tions, the spatial organization of metabolism within a cell re-
mains poorly understood due to the technical challenges of
measuring subcellular location. In a typical metabolomic ex-
periment, cell lysates are analyzed and the results therefore
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only provide average concentrations of metabolites from the
entire cell. Although organelles can be efficiently purified for
metabolic evaluation, co-purified contaminates are a consid-
erable challenge [3]. Metabolite interactions with the outer
membrane leaflet or its associated proteins, for example, can
complicate data analysis. For mitochondria, which are the
focus of the current work, the intermembrane space creates
additional difficulties. Proteomic analyses suffer from the
same problems [4]. High-resolution microscopy can be
applied to image proteins within a cell, but this does not re-
flect protein activity. Functional assays from purified mito-
chondria can be insightful; however, it is difficult to confirm
that protein activity occurs within the mitochondrial matrix.
Further, an incomplete understanding of mitochondrial
carrier systems has limited our ability to study
compartmentalization by manipulating metabolite transport
[5]. Thus, strategies to localize metabolic transformations
within subcellular compartments such as mitochondria are
highly needed.
In this work, we were specifically interested in localizing
the enzyme lactate dehydrogenase (LDH) within cells. Re-
cent studies have shown that some cancer cells use lactate
in vitro and in vivo as a primary carbon source for meta-
bolic pathways in mitochondria, such as the tricarboxylic
acid (TCA) cycle [6–8]. LDH is required to incorporate
lactate carbon into TCA cycle intermediates. An interest-
ing question is whether this LDH activity occurs in the
cytosol and/or in mitochondria. When oxidizing lactate to
pyruvate, LDH simultaneously reduces NAD+ to NADH.
Neither NAD+ nor NADH can cross the inner mitochon-
drial membrane, and the ratio of NAD+ to NADH modu-
lates numerous biological processes in both the cytosol
and mitochondria. Thus, the location of LDH may select-
ively influence redox balance within subcellular compart-
ments and therefore have important regulatory
implications in cancer metabolism [9].
Methods
Cell culture and drug treatments
Unless otherwise noted, cells were cultured in
high-glucose Dulbecco’s Modified Eagle Medium
(DMEM, 4.5 g/L D-glucose) (Life Technologies) contain-
ing 10% Fetal Bovine Serum (FBS) (Life Technologies)
and 1% penicillin/streptomycin (Life Technologies) at
37 °C with 5% CO2. In each drug experiment, either
oxamate or GSK-2837808A (3-[[3-[(Cyclopropylamino)
sulfonyl]-7-(2,4-dimethoxy-5-pyrimidinyl)-4-quinolinyl]
amino]-5-(3,5-difluorophenoxy) benzoic acid, TOCRIS)
was added into the assay buffer. To account for effects
of DMSO, DMSO was added to the assay buffer in all
experiments (including oxamate conditions and vehicle
conditions). The final concentration of DMSO was 1%,
unless otherwise stated. Three biological replicates were
used for each condition tested.
Lactate production assay
Approximately 7 × 105 HeLa cells were seeded in a
12-well plate and allowed to attach overnight. Cells were
then washed and supplemented with FBS-free,
low-glucose media (1 g/L D-glucose) and treated with
oxamate, GSK-2837808A, or DMSO alone (vehicle). After
6 h, the culture media were collected and extracted as de-
scribed previously and detailed below [10]. Samples were
analyzed by liquid chromatography/mass spectrometry
(LC/MS) in negative ion mode with a triple quadrupole
mass spectrometer (6460, Agilent Technologies). Samples
were separated with a Luna Aminopropyl column (3 μm,
150 mm× 1.0 mm I.D., Phenomenex) coupled to an Agi-
lent 1260 LC system. A flow rate of 50 μL/min was used.
The mobile phases and linear gradient were A = 95%
water, 5% acetonitrile (ACN), 20 mM ammonium hydrox-
ide (NH4OH), 20 mM ammonium acetate (NH4Ac); B =
100% ACN; 85% B from 0 to 3 min, 85% to 50% B from 3
to 7 min, 50% to 5% B from 7 to 11 min, and 5% B from
11 to 13 min.
Purification of mitochondria
Mitochondria were purified as described previously [6].
Briefly, cells were harvested, pelleted, and re-suspended in
cold mitochondrial isolation media (MIM) (300 mM su-
crose, 10 mM HEPES, 0.2 mM EDTA, and 1 mg/mL bo-
vine serum albumin (BSA), pH 7.4) and then homogenized
with a glass-Teflon potter. Next, samples were centrifuged
at 700×g (4 °C) for 7 min to separate mitochondria from
the remaining cellular material. The supernatant was dec-
anted after centrifugation and set aside. The remaining pel-
lets were homogenized again in MIM to recover more
mitochondria. The supernatant was then pooled with the
supernatant from above and centrifuged at 10,000×g (4 °C)
for 10 min to obtain mitochondrial pellets. Mitochondrial
pellets were washed and quantified by performing a Brad-
ford assay, unless otherwise noted.
LDH activity assay
LDH activity was assessed in a 96-well plate. First, mitochon-
dria were purified from ~ 6× 107 HeLa cells as above. Mito-
chondrial pellets were then lysed with 1% triton X-100/50
mM Tris (pH 7.4). The mitochondrial lysates were treated
with oxamate, GSK-2837808A, or DMSO alone (vehicle).
The 1% triton X-100/50 mM Tris solution was used as a
negative control (blank). A standard mixture was prepared
containing phenazine methosulphate (360 μg/mL),
p-iodonitrotetrazolium violet (1.3 mg/mL), and NAD+
(340 μg/mL). A 50 μL aliquot of the standard mixture,
200 mM Tris (pH 8), and 50 mM lactate were added to each
well before adding 50 μL of sample (38 μg of mitochondrial
protein/well). The final concentration of DMSO was 0.4% in
all three conditions. The kinetic assay was run at 490 nm
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with a Cytation 5 microplate reader (BioTek), and LDH ac-
tivity was determined by the maximum slope.
Labeling whole cells with U-13C lactate
HeLa cells were grown to ~ 35% confluency in 100-mm
culture dishes. The culture media were then changed to fresh
low-glucose (5 mM) media supplemented with 3 mM
uniformly 13C-labeled lactate (U-13C lactate, Cambridge
Isotope Laboratories). Cells were treated with 50 mM
oxamate, 75 µM GSK-2837808A, or DMSO alone (vehicle)
for 24 h. The final concentration of DMSO was 0.3% in all
three conditions. After 24 h, cells were washed with
phosphate-buffered saline (PBS) and HPLC-grade water,
quenched with 1 mL cold HPLC-grade methanol, scraped
from the plate, and pelleted. Pellets were dried on a Speed-
Vac (Thermo Fisher Scientific) and subsequently lyophilized
(Labconco). Dried samples were weighed and extracted by
using the protocol described below [10]. Experiments were
performed with n= 3 cultures per sample group.
Oxygen consumption rate
Respiration of intact mitochondria was measured with an
XFp analyzer (Seahorse Bioscience) or a high-resolution
OROBOROS Oxygraph-2k respirometer (Oroboros Instru-
ments). For the Seahorse experiments, after purifying mito-
chondria from ~ 2 × 107 HeLa cells, approximately 8 μg of
mitochondrial pellets were re-suspended in cold mitochon-
dria assay solution (MAS, 70 mM sucrose, 220 mM man-
nitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES,
1 mM EGTA, and 0.2% (w/v) fatty acid-free BSA, pH 7.2)
with 10 mM lactate and 5 mM malate. Before measuring
respiration, mitochondria were brought to room
temperature. ADP (4 mM) was added to induce respir-
ation. The oxygen consumption rate (OCR) of HeLa mito-
chondria was monitored under three different conditions:
oxamate, GSK-2837808A, or DMSO alone (vehicle). To re-
move background contributions, the OCR value before the
addition of ADP was subtracted from the OCR value after
the addition of ADP (Fig. 3b). For assessing mitochondrial
function, no drugs or DMSO were added. Sample sizes
were used that produced OCR numbers within the recom-
mended range of the vendor. For the Oroboros experi-
ments, mitochondrial respiration media were used.
Approximately the same number of HeLa cell mitochon-
dria (300 μg mitochondrial protein) was added to each
chamber followed by metabolic substrates and inhibitors.
Labeling whole cells with 2-2H lactate prior to
mitochondrial purification
Cells were cultured in a T-150 flask until reaching 90%
confluency. Cells were then transferred to glucose-free
media for 4 h. After 4 h, cells were supplemented with
10 mM 2-2H lactate for 45 min prior to being washed,
harvested, and pelleted. For mitochondrial purification,
the cell pellets were re-suspended in 500 μL of cold
MIM with 100 mM oxamate. The isolated mitochondrial
pellets were lyophilized and subsequently treated with a
methanol/acetonitrile/water (2:2:1) solution prior to be-
ing reconstituted in 40 μL acetonitrile/water (1:1) per
milligram dry weight. LC/MS analysis was performed as
described below.
Labeling purified mitochondria with U-13C lactate
Approximately 2 × 108 HeLa cells were harvested at 90%
confluence. Mitochondria were purified as above. Purified
mitochondria were split into wells (170 μg of mitochon-
drial protein/well) and incubated in 1 mL MAS buffer with
5 mM malate and 5 mM lactate. Samples were treated with
oxamate, GSK-2837808A, or DMSO alone (vehicle) for
10 min. The final concentration of DMSO was 0.3% in all
three conditions. After 10 min, 10 mM U-13C lactate was
added to the MAS buffer for 20 min before harvesting.
Mitochondrial pellets were washed, collected, and snap
frozen in liquid nitrogen prior to extraction.
Metabolite extraction and LC/MS analysis
Cell pellets or purified mitochondria were extracted and
analyzed by LC/MS as described before [6, 10]. Cell pellets
were treated with a methanol/acetonitrile/water (2:2:1) so-
lution and reconstituted in 40 μL acetonitrile/water (1:1)
per milligram dry weight. Mitochondrial pellets were
treated with a methanol/acetonitrile/water (2:2:1) solution
and reconstituted in 50 μL acetonitrile/water (1:1) per
170 μg of mitochondrial protein, unless otherwise noted.
Samples were separated with a Luna Aminopropyl column
(3 μm, 150 mm× 1.0 mm I.D., Phenomenex) coupled to a
Dionex UltiMate® 3000 RSLCnano LC system. MS detec-
tion was performed on a Thermo Q Exactive Plus mass
spectrometer (Thermo Fischer Scientific) in negative ion
mode at 140,000 resolving power. The column was used
in hydrophilic interaction mode with a flow rate of 50 μL/
min. The following mobile phases and linear gradient
were used: A = 95% water, 5% ACN, 20 mM NH4OH,
20 mM NH4Ac; B = 95% ACN, 5% water; 100% B from 0
to 3 min, 100% B to 0% B from 3 to 40 min, and 0% B
from 40 to 45 min.
Statistical analysis
Data are reported as means ± SD. Dataset comparisons
were performed with a Student’s unpaired, two-tailed t test.
Results
Here, we describe an approach to localize metabolic reac-
tions to the mitochondrial matrix by exploiting the limited
permeability of the inner mitochondrial membrane to small
molecule inhibitors. The method, which we refer to as
transport-exclusion pharmacology, assumes that the activity
of enzymes in the mitochondrial matrix is only affected by
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exogenously delivered inhibitors that cross the inner mito-
chondrial membrane. When an inhibitor without access to
the mitochondrial matrix does not affect enzymatic activity
in whole-cell analyses, this suggests that the enzyme is ex-
clusively localized to the matrix (Fig. 1). When whole-cell
experiments show reduced enzymatic activity, in contrast,
it indicates that at least some enzyme has an extramito-
chondrial location. To identify cases of redundancy where
enzymes (e.g., LDH) are located in both the mitochondrial
matrix as well as other cellular locations with potentially
differential access to inhibitors, the same experiment can
be repeated on isolated mitochondria. When testing iso-
lated mitochondria with inhibitors that do not have access
to the matrix and enzyme activity is unaffected, this indi-
cates enzyme localization to the matrix. All results can be
validated by using homogenized mitochondria, which al-
lows inhibitors to access matrix-localized proteins inde-
pendent of their transport properties. We applied this
strategy to localize LDH in HeLa cells here because we
already evaluated the spatial organization of LDH in these
cells with other methods previously [6].
Functional LDH is a homo- or heterotetramer made up
of LDHA and LDHB subunits [11]. We considered two
compounds (oxamate and GSK-29837808A) known to in-
hibit both LDHA and LDHB subunits at the concentra-
tions we used [12–16]. We note that because our
inhibition experiments are not specific to enzyme subtype,
we cannot distinguish between LDHA and LDHB in the
analyses. It has been shown previously, however, that
LDHB is concentrated in HeLa cell mitochondria [6].
Oxamate is an isoelectric and isosteric analogue of pyru-
vate, having a dissociation constant with LDH/NADH that
is close to the Michaelis-Menten constant of pyruvate
[17]. Additionally, oxamate is transported into mitochon-
dria by the mitochondrial pyruvate carrier [18].
GSK-29837808A, on the other hand, is a competitive in-
hibitor of NAD, which cannot cross the inner mitochon-
drial membrane [12]. When given to intact HeLa cells,
both compounds inhibited LDH activity as measured by
the amount of lactate excreted into the media (Fig. 2).
Consistent with previous reports, we found that micromo-
lar concentrations of GSK-29837808A achieved the same
level of LDH inhibition as millimolar concentrations of
oxamate [13]. These results show that, as expected, LDH
is not exclusively localized to HeLa cell mitochondria.
We next wished to consider the possibility that LDH
is present in both the cytosol and mitochondria, as has
been suggested previously [19–23]. To evaluate mito-
chondrial metabolism specifically, we purified intact
mitochondria from HeLa cells and verified their integrity
and metabolic function. We determined the respiratory
control ratio (state 3/state 4) of purified HeLa cell mito-
chondria to be > 8. We also confirmed that our purified
HeLa cell mitochondria responded to the addition of
various substrates and inhibitors as expected (Add-
itional files 1 and 2: Figures S1 and S2). After purifying
intact mitochondria from HeLa cells, we treated them
with oxamate or GSK-29837808A and then assessed
LDH activity in either of two ways. First, we measured
the ADP-supported OCR of vehicle controls and com-
pared them to purified mitochondria treated with drug
(Fig. 3a). We used a concentration of 50 mM for oxa-
mate and 75 μM for GSK-29837808A, since these con-
centrations were determined to have comparable effects
on LDH activity in HeLa cells (Fig. 2). Importantly, puri-
fied mitochondria were only provided malate (5 mM)
and lactate (10 mM) as carbon sources in these experi-
ments. We note that purified HeLa mitochondria do not
respire well when only provided malate or lactate alone,
presumably because they need a source of oxaloacetate
and acetyl-CoA for citrate synthase. Thus, under our ex-
perimental conditions, respiration can only be supported
by LDH oxidation of lactate. Interestingly, we found oxa-
mate reduced the OCR by ~ 70% while GSK-29837808A
had no statistically significant effect relative to vehicle
controls (Fig. 3b).
A B
Fig. 1 Transport-exclusion pharmacology to localize enzyme activity within a cell. a When the enzyme is localized to the cytosol, both inhibitors block
activity. b When the enzyme is localized to mitochondria, only IS blocks activity. E represents the enzyme of interest localized in cytosol or mitochondria. IS
represents an inhibitor of E that is transported into mitochondria. IB represents an inhibitor of E that cannot be transported into mitochondria
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As a second method to assess LDH activity in purified
HeLa cell mitochondria, we also used stable isotope
tracers and LC/MS. After purifying HeLa mitochondria,
we incubated them in the same buffer as above, but we
added U-13C lactate for 20 min. We then used the in-
corporation of two 13C labels into citrate as an indicator
of LDH activity. The M + 2 isotopologue of citrate re-
sults from the sequential actions of LDH, the pyruvate
dehydrogenase complex, and citrate synthase. Consistent
with the OCR data, we found that oxamate reduced
citrate labeling while GSK-29837808A treatment led to
no statistically significant change relative to vehicle
B
A
Fig. 2 Oxamate and GSK-2837808A inhibit LDH activity in HeLa cells. a Oxamate resembles pyruvate in structure and competes with pyruvate for
LDH binding. GSK-2837808A competes with NAD for LDH binding. b Different concentrations of oxamate (oxa) and GSK-2837808A (GSK)
achieved a similar level of LDH inhibition, as determined by measuring lactate excreted to the HeLa extracellular media after drug treatment. All
data shown are averages from groups of n = 3. n.s., no statistical difference
A
B C
Fig. 3 Only oxamate significantly inhibits LDH activity when drugs are given to purified mitochondria from HeLa cells. a Mitochondria were first
purified from HeLa cells and then given oxamate (oxa) or GSK-2837808A (GSK). b Oxygen consumption rate (OCR) from purified mitochondria
provided lactate as a respiratory substrate. Each condition is compared to a vehicle control having an identical preparation, but without drug
treatment. c M+ 2 labeling in citrate from purified mitochondria provided U-13C lactate as a respiratory substrate. The M + 2 isotopologue is
significantly decreased due to oxamate, but not significantly different from the vehicle control due to GSK-2837808A treatment. All data shown
are averages from groups of n = 3. **p < 0.01; n.s., no statistical difference
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controls (Fig. 3c). Together, these data are consistent with
LDH localization to the mitochondrial matrix, where it is
accessible to oxamate but not GSK-29837808A (rather
than localization to the outer membrane or intermem-
brane space).
Having established that U-13C lactate labeled TCA cycle
intermediates differently when purified mitochondria were
treated with oxamate versus GSK-29837808A, we sought to
repeat the experiment with whole cells. We cultured HeLa
cells in media containing 5 mM glucose and 3 mM U-13C
lactate for 24 h. For the duration of labeling, samples were
treated either with 50 mM oxamate, 75 μM
GSK-29837808A, or vehicle control (DMSO alone). After
24 h, intact cells were harvested and extracted for LC/MS
analysis. Strikingly, we observed only minimal labeling of
TCA cycle intermediates in cells treated with oxamate
(Fig. 4). In contrast, labeling of cells treated with
GSK-29837808A was not significantly different than vehicle
controls. Notably, the labeling patterns we observed here for
whole cells were consistent with the results obtained when
the same experiment was performed on purified mitochon-
dria (Fig. 3c). As described above (Fig. 2b), oxamate and
GSK-29837808A both significantly decreased lactate produc-
tion in whole cells when administered at the same concen-
tration as in Fig. 4. Taken together, these results are
consistent with both oxamate and GSK-29837808A decreas-
ing the reduction of pyruvate to lactate by inhibiting cyto-
solic LDH, but only oxamate having access to inhibit
mitochondrial LDH that is used for lactate oxidation. We
note that the level of AMP was increased in HeLa cells
treated with oxamate but not HeLa cells treated with
GSK-29837808A, suggesting that mitochondrial LDH
activity may influence cellular energy status (Additional file 3:
Figure S3) [24].
To validate that 75 μM GSK-29837808A can effect-
ively inhibit mitochondrial LDH, we homogenized puri-
fied mitochondria and assessed LDH activity after drug
treatment by using a colorimetric assay. Compared to
vehicle control, both 50 mM oxamate and 75 μM
GSK-29837808A decreased LDH activity by more than
five-fold (Fig. 5). The decrease in LDH activity was less
with a lower concentration of oxamate, but the results
were comparable (Additional file 4: Figure S4). These
data indicate that GSK-29837808A can only access LDH
after the inner mitochondrial membrane has been dis-
rupted, which suggests that at least some LDH enzyme
is localized to the HeLa mitochondrial matrix. Although
we have focused on the metabolism of lactate by HeLa
cells in the current study, additional data support that
oxidation of lactate by mitochondria is relevant to other
Fig. 4 TCA cycle labeling from U-13C lactate is decreased when whole cells are treated with oxamate, but not when whole cells are treated with
GSK-2837808A. These results are consistent with oxamate (oxa) inhibiting cytosolic and mitochondrial LDH, but with GSK-2837808A (GSK) only
inhibiting cytosolic LDH. HeLa cells were labeled with U-13C lactate for 24 h prior to analysis of whole-cell extracts by LC/MS. Data shown are
averages from groups of n = 3. ***p < 0.001. n.s., no statistical significance. Left y axis shows labeling from 0 to 100%. Right y axis shows a
zoomed-in scale for 13C isotopologues (inset)
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cancer cell lines (e.g., Hep G2 and H460) as well (Add-
itional file 5: Figure S5).
Discussion
Increasing evidence supports that lactate is not only a
prominent fuel in cancer cells, but also a major source
of carbon for anabolic processes such as lipid synthesis
[6–8, 25]. Utilization of lactate in this capacity requires
that lactate be oxidized by LDH, which could potentially
occur in the cytosolic and/or mitochondrial compart-
ments of a cancer cell. While the difference between
cytosolic and mitochondrial LDH activity only changes
the location of two electrons, the regulatory implications
of a compartmentalized shift in redox homeostasis are
potentially significant. Many metabolic enzymes are reg-
ulated by the ratio of NAD+ to NADH, such as glyceral-
dehyde 3-phosphate dehydrogenase in the cytosol and
isocitrate dehydrogenase 3 in mitochondria [26]. The
site of LDH activity may therefore have an important ef-
fect on metabolic fluxes. Oxidation of lactate by cyto-
solic LDH, for example, may slow glycolytic flux and
glucose consumption, while oxidation of lactate by mito-
chondrial LDH may promote lipid synthesis via the ac-
cumulation of citrate [6, 9].
Although the possibility of a mitochondrial LDH has
been considered for several decades, disagreements persist
about its precise location and its biochemical role, as has
recently been reviewed in detail [27–29]. Progress in
the field has been complicated by the technical limi-
tations of localizing lactate metabolism within differ-
ent subcellular compartments. Mitochondrial LDH
cannot be assessed by tracing labels from 13C-lactate
because of cytosolic lactate-pyruvate exchange [30].
Imaging approaches have generally provided limited
resolution to localize LDH to the mitochondrial
matrix. Functional assays examining whether mamma-
lian mitochondrial preparations oxidize lactate have
provided mixed results. Thus, alternative experimental
approaches to provide additional information about
mitochondrial lactate metabolism are needed.
We have described a strategy that exploits unique mito-
chondrial transport properties of different small-molecule
inhibitors (oxamate and GSK-29837808A) to assess LDH
location within cells. Interestingly, when evaluating intact
purified mitochondria, oxamate decreased LDH activity
but GSK-29837808A did not. Yet, both drugs had similar
effects on LDH activity once mitochondria were disrupted,
indicating differential access to LDH in previous experi-
ments. Even though we have applied the approach to
LDH here, the same approach can be broadly applied to
investigate the spatial location of other enzymes. These
data will be highly complementary to metabolomic and
proteomic experiments performed on purified mitochon-
dria and may provide key insights as we seek to under-
stand the ways in which mitochondria are functionally
integrated within the cell. We note that employing
transport-exclusion pharmacology requires having inhibi-
tors with unique biochemical properties to mediate sub-
cellular distribution, which are not available for many
enzymes. However, we are optimistic that the rapidly
growing interest in mitochondrial biology will inspire the
development of such drugs not only for these types of
A
B
Fig. 5 Both oxamate and GSK-2837808A significantly inhibit LDH activity in HeLa cell mitochondrial homogenates. a Mitochondria were first purified from
HeLa cells and then homogenized before treating with oxamate (oxa) or GSK-2837808A (GSK). b LDH activity was measured by using a colorimetric assay.
Both drugs significantly inhibited LDH activity compared to vehicle control. Data shown are averages from groups of n= 3. ***p< 0.001
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experiments but also for their potential therapeutic signifi-
cance in selectively targeting disease processes within spe-
cific subcellular compartments.
Conclusions
Mitochondria isolated from HeLa cells have the capacity to
oxidize lactate, suggesting the presence of a mitochondrial
LDH. Of particular interest, however, is the location of the
enzyme within mitochondria. Its association with the outer
mitochondrial membrane, the intermembrane space, or
the outer leaflet of the inner mitochondrial membrane af-
fects cytosolic redox balance. Its association with the inner
leaflet of the inner membrane or the matrix, in contrast, af-
fects mitochondrial redox balance. Intact purified mito-
chondria given oxamate, a competitive inhibitor of
pyruvate, show decreased LDH activity. GSK-29837808A,
which is a competitive inhibitor of NAD, only affected
LDH activity in mitochondrial homogenates when the
inner mitochondrial membrane had been disrupted.
These data are consistent with some mitochondrial LDH
that is accessible to oxamate but not GSK-29837808A.
Our approach of using small-molecule inhibitors with
different mitochondrial transport properties to localize
protein activity is broadly applicable to the study of
other enzymes.
Additional files
Additional file 1: Figure S1. OCR data from purified HeLa cell
mitochondria. State 1 data are from purified mitochondria alone. State 2
data are from purified mitochondria incubated with 10 mM lactate and
5 mM malate, without ADP. State 3 data are from purified mitochondria
incubated with 10 mM lactate, 5 mM malate, and 4 mM ADP. Data shown
are averages from groups of n = 3. **p < 0.01 and ***p < 0.001. (PDF 18 kb)
Additional file 2: Figure S2. Respiration of purified mitochondria from
HeLa cells. OCR was measured in response to the addition of mitochondria
(mito), substrates (pyruvate/malate, pyr/mal; ADP; succinate, suc), inhibitors
(rotenone, Rot; oligomycin, Oligo; antimycin A, AntA), an uncoupler (FCCP),
and cytochrome c (Cyt c). (PDF 55 kb)
Additional file 3: Figure S3. AMP levels are increased after treating
HeLa cells with oxamate (oxa) for 24 h but not after treating them with
GSK-2837808A (GSK) for 24 h. No significant changes in the levels of ATP
or ADP were found. All data shown are averages from groups of n = 3.
*p < 0.05; n.s., no statistical significance. (PDF 42 kb)
Additional file 4: Figure S4. Response of HeLa cells to different
concentrations of oxamate. a HeLa cell mitochondrial lysates were treated
with oxamate, and LDH activity was measured by using a colorimetric assay.
b HeLa cell proliferation was measured after treatment with oxamate for
24 h. No DMSO was added to the samples. Data shown are averages from
groups of n = 3. ***p < 0.001; n.s., no statistical significance. (PDF 60 kb)
Additional file 5: Figure S5. Deuterium labels from 2-2H lactate enter
Hep G2 and H460 mitochondria. a Lactate can be exchanged with
pyruvate in the cytosol or lactate can be transported into mitochondria.
We sought to distinguish between these two possibilities by labeling
cells with 2-2H lactate. We then used LC/MS to localize 2-2H lactate to
mitochondria. b, c Mass spectra from mitochondria purified from cells
cultured for 45 min in 2-2H lactate enriched media. b Purified
mitochondria from Hep G2, a human liver cancer cell line. c Purified
mitochondria from H460, a human lung cancer cell line. These results
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